Barclays Turns Bearish on Janux: Lead Program JANX007 Loses Confidence
Barclays cut Janux Therapeutics to Underweight, citing doubts on JANX007 and limited near-term upside despite long-term potential.
/ 2 items
Barclays cut Janux Therapeutics to Underweight, citing doubts on JANX007 and limited near-term upside despite long-term potential.
Vir Biotech beats Q4 estimates by a mile, announces $335M+ partnership with Astellas, and shares promising new data for its prostate cancer drug. Strong cash position funds operations into 2028.